Press release content from Business Wire. The AP news staff was not involved in its creation.
Gilead Sciences and Gritstone Announce Collaboration Utilizing Gritstone’s Vaccine Platform Technology for HIV Cure
February 1, 2021 GMT
FOSTER CITY, Calif. & EMERYVILLE, Calif. (BUSINESS WIRE) Feb 1, 2021
Gilead Sciences, Inc. (Nasdaq: GILD) and Gritstone Oncology, Inc. (Nasdaq: GRTS), a clinical-stage biotechnology company developing next generation cancer and infectious disease immunotherapies, today announced that the companies have entered into a collaboration, option and license agreement to research and develop a vaccine-based immunotherapy as part of Gilead’s efforts to find a curative treatment for human immunodeficiency virus (HIV) infection.
endIndex:
Dumaguete City (CNN Philippines, February 1) Negros Oriental recorded its first case of COVID-19 reinfection over the weekend.
Provincial IATF Ground Commander Dr. Liland Estacion on Monday said the patient is a 46-year-old frontliner working at the Local Disaster Risk Reduction Management Office of Guihulngan City.
Estacion added the patient was symptomatic after testing positive last January 25 and has been admitted in a government isolation facility.
He was initially infected on October 30 last year during the transport of a COVID-19 patient from Guihulngan to Dumaguete City. He recovered days after and returned to work after finishing his required isolation.
Estacion explained that when a person is infected with COVID-19, the body will develop antibodies which can only last for at least three months, and might get infected again.